Brian J. Francica

2.4k total citations · 1 hit paper
24 papers, 944 citations indexed

About

Brian J. Francica is a scholar working on Immunology, Oncology and Pharmacology. According to data from OpenAlex, Brian J. Francica has authored 24 papers receiving a total of 944 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Immunology, 15 papers in Oncology and 5 papers in Pharmacology. Recurrent topics in Brian J. Francica's work include Cancer Immunotherapy and Biomarkers (11 papers), Immunotherapy and Immune Responses (10 papers) and interferon and immune responses (5 papers). Brian J. Francica is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Immunotherapy and Immune Responses (10 papers) and interferon and immune responses (5 papers). Brian J. Francica collaborates with scholars based in United States, Canada and Taiwan. Brian J. Francica's co-authors include Charles G. Drake, Christina M. Kochel, Thomas R. Nirschl, Christopher J. Nirschl, Andrew B. Sharabi, Esteban Velarde, Theodore L. DeWeese, Robert A. Anders, Adrie van Bokhoven and Allison Martin and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Brian J. Francica

24 papers receiving 932 citations

Hit Papers

Stereotactic Radiation Therapy Augments Antigen-Specific ... 2014 2026 2018 2022 2014 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
    2014 510 citations Andrew B. Sharabi, Christopher J. Nirschl et al. Cancer Immunology Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brian J. Francica United States 9 692 488 272 133 96 24 944
Christina M. Kochel United States 9 952 1.4× 644 1.3× 319 1.2× 136 1.0× 155 1.6× 15 1.2k
Amy L. Adlard United Kingdom 4 935 1.4× 546 1.1× 361 1.3× 97 0.7× 143 1.5× 5 1.2k
Grazyna Lipowska‐Bhalla United Kingdom 7 954 1.4× 489 1.0× 369 1.4× 118 0.9× 142 1.5× 11 1.2k
Anne Marie Yang United States 3 738 1.1× 611 1.3× 191 0.7× 81 0.6× 58 0.6× 5 957
Yasuko Tada Japan 6 877 1.3× 691 1.4× 270 1.0× 167 1.3× 57 0.6× 8 1.2k
Conor McKenna United Kingdom 4 831 1.2× 393 0.8× 348 1.3× 93 0.7× 138 1.4× 5 1.0k
Steven K. Seung United States 13 509 0.7× 379 0.8× 219 0.8× 91 0.7× 85 0.9× 24 831
Felix Klug Germany 8 650 0.9× 616 1.3× 181 0.7× 192 1.4× 54 0.6× 8 1.0k
Benjamin Cottam United States 11 672 1.0× 628 1.3× 124 0.5× 153 1.2× 67 0.7× 14 949
W.E. Gillanders United States 5 826 1.2× 493 1.0× 145 0.5× 231 1.7× 64 0.7× 6 1.0k

Countries citing papers authored by Brian J. Francica

Since Specialization
Citations

This map shows the geographic impact of Brian J. Francica's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian J. Francica with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian J. Francica more than expected).

Fields of papers citing papers by Brian J. Francica

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian J. Francica. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian J. Francica. The network helps show where Brian J. Francica may publish in the future.

Co-authorship network of co-authors of Brian J. Francica

This figure shows the co-authorship network connecting the top 25 collaborators of Brian J. Francica. A scholar is included among the top collaborators of Brian J. Francica based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian J. Francica. Brian J. Francica is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Daver, Naval, Abhishek Maiti, David A. Sallman, et al.. (2024). A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify).. Journal of Clinical Oncology. 42(16_suppl). TPS6586–TPS6586. 5 indexed citations
2.
Francica, Brian J., Anja Holtz, Justine Lopez, et al.. (2023). Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors. Cancer Research Communications. 3(8). 1486–1500. 20 indexed citations
3.
Chen, Valerie, Brian J. Francica, David Hsieh, et al.. (2023). Abstract 1636: Generation of novel potent human TREX1 inhibitors facilitated by crystallography. Cancer Research. 83(7_Supplement). 1636–1636. 2 indexed citations
4.
Chen, Shuming, Seoho Lee, Tracee L. McMiller, et al.. (2023). Abstract 4159: The COX-2/PGE2 pathway as a mediator of resistance to anti-PD-1 therapy. Cancer Research. 83(7_Supplement). 4159–4159. 2 indexed citations
5.
Shook, David, Ana Rolo, Brian J. Francica, et al.. (2022). Characterization of convergent thickening, a major convergence force producing morphogenic movement in amphibians. eLife. 11. 11 indexed citations
6.
Francica, Brian J., Justine Lopez, Anja Holtz, et al.. (2022). Abstract 1333: Dual blockade of the EP2 and EP4 PGE2 receptors with TPST-1495 is an optimal approach for drugging the prostaglandin pathway. Cancer Research. 82(12_Supplement). 1333–1333. 1 indexed citations
7.
Davar, Diwakar, John D. Powderly, Susanna V. Ulahannan, et al.. (2022). A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in subjects with solid tumors.. Journal of Clinical Oncology. 40(16_suppl). TPS2696–TPS2696. 5 indexed citations
8.
Suter, Emily, Eva M. Schmid, Andrew R. Harris, et al.. (2021). Antibody:CD47 ratio regulates macrophage phagocytosis through competitive receptor phosphorylation. Cell Reports. 36(8). 109587–109587. 34 indexed citations
9.
Deng, Weiwen, Anthony L. Desbien, Gabrielle L. Reiner, et al.. (2020). Abstract PR09: ADU-S100 (MIW815) synergizes with checkpoint blockade to elicit an antitumor CD8+ T-cell response to control distal tumors. Cancer Immunology Research. 8(4_Supplement). PR09–PR09. 4 indexed citations
10.
Francica, Brian J., Ali Ghasemzadeh, Anthony L. Desbien, et al.. (2018). TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors. Cancer Immunology Research. 6(4). 422–433. 67 indexed citations
11.
Gordy, James T., Kun Luo, Brian J. Francica, Charles G. Drake, & Richard B. Markham. (2018). Anti-IL-10–mediated Enhancement of Antitumor Efficacy of a Dendritic Cell–targeting MIP3α-gp100 Vaccine in the B16F10 Mouse Melanoma Model Is Dependent on Type I Interferons. Journal of Immunotherapy. 41(4). 181–189. 18 indexed citations
12.
Shen, Ying‐Chun, Ali Ghasemzadeh, Christina M. Kochel, et al.. (2017). Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model. Prostate Cancer and Prostatic Diseases. 21(1). 113–125. 41 indexed citations
13.
Marciscano, Ariel E., Thomas R. Nirschl, Brian J. Francica, et al.. (2016). Does Prophylactic Nodal Irradiation Inhibit Potential Synergy Between Radiation Therapy and Immunotherapy?. International Journal of Radiation Oncology*Biology*Physics. 96(2). S88–S88. 8 indexed citations
14.
Jackson, Christopher M., Christina M. Kochel, Christopher J. Nirschl, et al.. (2015). Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination. Clinical Cancer Research. 22(5). 1161–1172. 54 indexed citations
15.
Martin, Allison, Thomas R. Nirschl, Christopher J. Nirschl, et al.. (2015). Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer and Prostatic Diseases. 18(4). 325–332. 142 indexed citations
16.
Shen, Ying‐Chun, Christina M. Kochel, Brian J. Francica, et al.. (2015). Abstract 267: Combining androgen deprivation with immune checkpoint blockade delays the development of castration resistance in a murine model of prostate cancer. Cancer Research. 75(15_Supplement). 267–267. 2 indexed citations
17.
Sharabi, Andrew B., Christopher J. Nirschl, Christina M. Kochel, et al.. (2014). Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. Cancer Immunology Research. 3(4). 345–355. 510 indexed citations breakdown →
18.
Sharabi, Andrew B., Christopher J. Nirschl, Thomas R. Nirschl, et al.. (2014). Role of Radiation Therapy in Inducing Antigen Specific Antitumor Immune Responses When Combined With Anti-PD1 Checkpoint Blockade: Mechanism and Clinical Implications. International Journal of Radiation Oncology*Biology*Physics. 90(1). S1–S1. 7 indexed citations
19.
Sharabi, Andrew B., Christopher J. Nirschl, Brian J. Francica, et al.. (2014). Abstract 635: Antigen-specific immune responses in melanoma using stereotactic radiotherapy combined with anti-PD1 checkpoint blockade. Cancer Research. 74(19_Supplement). 635–635. 1 indexed citations
20.
Nirschl, Christopher J., Christina Ceccato, Angela Alme, Brian J. Francica, & Charles G. Drake. (2013). Expression of neuropilin-1 on in vivo induced regulatory T cells. Journal for ImmunoTherapy of Cancer. 1(S1). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christina M. Kochel Breakdown of academic impact, for papers by Amy L. Adlard Breakdown of academic impact, for papers by Grazyna Lipowska‐Bhalla Breakdown of academic impact, for papers by Anne Marie Yang Breakdown of academic impact, for papers by Yasuko Tada Breakdown of academic impact, for papers by Conor McKenna Breakdown of academic impact, for papers by Steven K. Seung Breakdown of academic impact, for papers by Felix Klug Breakdown of academic impact, for papers by Benjamin Cottam Breakdown of academic impact, for papers by W.E. Gillanders
Rankless by CCL
2026